Table 3

Agreement between NCRAS registry and CAP on TNM stage

n=1356	NCRAS (n)	CAP (n)	Kappa (κ)	95% CI
TNM stage (2002–2009)
T1/T2	91	218	0.55	0.40 to 0.69
T3	21	242	0.33	0.15 to 0.51
T4/N1/M1	72	122	0.53	0.38 to 0.67
Overall	184	582	0.47	0.43 to 0.50
TNM stage (2010–2015)
T1/T2	64	57	0.45	0.28 to 0.62
T3	40	90	0.25	0.08 to 0.41
T4/N1/M1	117	84	0.41	0.28 to 0.55
Overall	221	231	0.34	0.27 to 0.37
TNM stage (overall)
T1/T2	155	275	0.53	0.42 to 0.64
T3	61	332	0.29	0.17 to 0.41
T4/N1/M1	189	206	0.47	0.37 to 0.57
Overall	405	813	0.41	0.37 to 0.51

CAP, Cluster randomised triAl of PSA testing for Prostate cancer; NCRAS, National Cancer Registration and Analysis Service; TNM, tumour, node, metastases.